Track topics on Twitter Track topics that are important to you
Dr Cath O'Neill, chief executive of SkinBioTherapeutics PLC (LON:SBTX), tells Proactive Investors the 'cream' formulation of its SkinBiotix technology has passed effectiveness studies in models of skin.
The cream formulation will now undergo further testing for stability in the coming weeks.
Original Article: 'Huge milestone' for SkinBioTherapeutics with cream formulation successNEXT ARTICLE
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...